SB 1026 creates a new section of Missouri law regulating “intoxicating cannabinoids,” defined broadly to include cannabinoids that produce an intoxicating effect, including certain THC-related compounds and precursors that become intoxicating when heated or otherwise processed. The bill excludes cannabidiol (CBD) from that definition. It does not ban the sale of these products, but it sets conditions for lawful sales in Missouri.
Under the bill, intoxicating cannabinoid products could be sold only to adults 21 and older after age verification, and sellers would have to comply with testing, safety, packaging, labeling, and other rules issued by the Department of Health and Senior Services. The department would also be required to adopt rules on potency limits, recalls, advertising standards, and enforcement procedures. Sellers would need to register annually with the department and pay a $1,000 fee, with a 45-day grace period for existing sellers once the law takes effect.
The bill would add section 195.900 to chapter 195, RSMo, creating a new regulatory framework for intoxicating cannabinoid products in Missouri. It would give the Department of Health and Senior Services authority to regulate product safety, labeling, potency, recalls, advertising, registration, and enforcement, while also imposing age restrictions and registration requirements on businesses selling these products. The bill would affect retailers, manufacturers, and distributors of hemp-derived and other intoxicating cannabinoid products, but would not apply to CBD as defined in the bill.
Based on the bill text and available context, the measure appears to be a regulatory response to the growing market for intoxicating hemp- and cannabis-derived products rather than a prohibition measure. The absence of recorded committee discussion or votes makes it difficult to identify a formal legislative consensus, but the structure of the bill suggests an intent to allow sales while imposing public-health safeguards. Overall, the bill’s tone is precautionary and administrative, focusing on consumer protection and state oversight.
The main points of potential contention are the breadth of the definition of “intoxicating cannabinoids,” which could capture a wide range of hemp-derived or chemically altered products, and the extent of state regulation over a market that some may view as already legal or lightly regulated. Businesses may object to the annual registration fee, compliance costs, and possible potency or advertising restrictions, while supporters are likely to emphasize youth access prevention, product safety, and enforcement authority. Because no committee transcript or vote record is available, specific named opponents or supporters cannot be identified from the provided materials.